Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-08-10 , DOI: 10.1111/dom.14520
Marcus Hompesch ₁ , Aleksandra Hawryluk ₂ , Moises Hernandez ₁ , Beena Uchil ₃ , Alyssa Wilmington ₄ , Lucas Peterson ₄

Affiliation

To show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence between Myxredlin, a novel, ready-to-use regular human insulin 1 U/mL formulation (BAX-HI), and Novolin R 100 U/mL concentrate diluted to 1 U/mL (NOVO-HI).

中文翻译：

在健康男性中，0.9% 氯化钠即用型输液 1 U/mL 和 100 U/mL 浓缩液中的常规人胰岛素（rDNA 来源）的药代动力学和药效学生物等效性

显示 Myxredlin（一种新型的即用型常规人胰岛素 1 U/mL 制剂 (BAX-HI) 与稀释至 1 U/mL 的 Novolin R 100 U/mL 浓缩物）之间的药代动力学 (PK) 和药效学 (PD) 生物等效性毫升 (NOVO-HI)。

更新日期：2021-08-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文